Compare 8x8 Inc (EGHT) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Enveric Biosciences Inc — how do they compare? 8x8 Inc trades at $2.2 (market cap $307.65M), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: 8x8 Inc is far larger — about 46× Enveric Biosciences Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Enveric Biosciences Inc for 14 Days on average.
| EGHT | ENVB | |
|---|---|---|
Market Cap | $307.65M | $6.69M |
Volume | 750,629 | 41,141 |
Sector | Technology | Health |
52-Week High | $2.76 | $10.80 |
52-Week Low | $1.59 | $1.27 |
Typical Hold Time | 16 Days | 14 Days |
Enterprise Value | $574.57M | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.14, down 1.38% today, with a bullish technical signal from moving averages and strong momentum indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client implementations and AI product growth, while analyst consensus targets $19.77 with mixed ratings.
The outlook suggests potential upside if profitability materializes as projected, supported by operational efficiency gains and AI adoption. Key risks include high debt levels, negative cash flow, and competitive pressures in the communications software sector that could challenge margin expansion.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
